companydata.dkcompanydata.dk

Ascendis Pharma Growth Disorders A/S: Financial statements 2015

CVR: 32323677

Source: annual report 2015, Danish Business Authority

01/01/2015 – 31/12/2015

Ascendis Pharma Growth Disorders A/S (CVR 32323677) has filed annual accounts for 2015. In 2015, the company reported a gross profit of EUR -2,500,794 and a net result of EUR -2,641,290 compared with EUR -602,535 the year before. Equity in the 2015 report amounted to EUR -3,194,023.

Gross Profit
EUR -2,500,794
Profit/Loss
EUR -2,641,290
Equity
EUR -3,194,023
Total Assets
EUR 503,030

Development

YearRevenueGross ProfitProfit/LossEquityEmployees
2015--2.5M EUR-2.6M EUR-3.2M EUR-
2014--507K EUR-603K EUR-553K EUR-
2013--23K-33K89K-

Official annual report

View the official annual report directly on the page with a Pro subscription.

How creditworthy is Ascendis Pharma Growth Disorders A/S?

See the CDS score and get a full credit report with recommended credit limit and payment terms.

Read about the CDS score

Events in 2015

Ascendis Pharma Growth Disorders A/S: The 2014 annual report is outMay 13, 2015

Ascendis Pharma Growth Disorders A/S has published its annual report for 2014. Gross profit came to DKK -507,089, and the net result was DKK -602,535.

About Ascendis Pharma Growth Disorders A/S

Ascendis Pharma Growth Disorders A/S is a Danish company of the type Aktieselskab based in Hellerup, founded in 2012. The company is registered under the industry Fremstilling af farmaceutiske præparater. The company was previously named ASCENDIS PHARMA, CIRCULATORY DISEASES DIVISION A/S and ASCENDIS PHARMA RELAXIN DIVISION A/S. The management consists of Jan Møller Mikkelsen. The board consists of Michael Wolff Jensen (chair), Anni Lotte Kirstine Pedersen and Jan Møller Mikkelsen. The company is owned by ASCENDIS PHARMA A/S. According to the 2025 annual report, the company had an average of 0 employees. In 2025, the company reported a gross profit of EUR -190,726,000 and a net result of EUR -225,725,000 compared with EUR -176,019,000 the year before. Equity in the 2025 report amounted to EUR -723,740,000.

Source: annual report 2025, Danish Business Authority